[Retracted] Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway

Zhou Zeng, Zhaolin Gao, Zhipei Zhang, Haibo Jiang, Yang Chang-quan, Jie Yang, Xiaobo XiaInternational Journal of Molecular Medicine 2024 · DOI · OpenAlex

Introduction

In 2019, a study published in the International Journal of Molecular Medicine proposed that the downregulation of the protein CKS1B could significantly restrain the progression of retinoblastoma, a common childhood eye cancer. However, as noted in a 2024 formal retraction notice, the article titled "Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway" has been withdrawn from the scientific record. This retraction highlights critical issues regarding data integrity and the reuse of experimental imagery across unrelated publications.

The Original Study's Claims

The original research aimed to identify novel therapeutic targets for retinoblastoma, the most common primary intraocular malignancy in children. The authors focused on CKS1B (Cyclin-dependent kinase regulatory subunit 1B), a protein associated with cell cycle regulation and often overexpressed in various cancers. The study claimed that by silencing CKS1B using gene downregulation techniques (likely siRNA or shRNA), researchers could effectively:

  • Inhibit Proliferation: Stop the rapid growth and division of cancer cells.
  • Reduce Migration and Invasion: Prevent the cancer from spreading to other tissues.
  • Suppress Angiogenesis: Halt the formation of new blood vessels required to sustain tumor growth.

The authors proposed that these therapeutic effects were achieved by modulating the MEK/ERK signaling pathway, a well-known "highway" for growth signals involved in cancer cell survival and proliferation. The study utilized standard molecular biology techniques, including Western blotting and functional assays, to support these conclusions.

Reasons for Retraction

The retraction was initiated after a "concerned reader" identified suspicious similarities in the experimental data. Specifically, the lumen formation assay data presented in Figure 5A—which was intended to demonstrate the inhibition of angiogenesis—were found to be "strikingly similar" to data appearing in a different form in another article. This other article was written by different authors at a different research institute and had been published in the journal Biomedicine & Pharmacotherapy prior to the submission of the CKS1B study.

The fact that the same data appeared in two unrelated studies from different institutions suggested a serious breach of research ethics. Upon being notified of these findings by the journal editors, the authors agreed with the decision to retract the paper. This agreement often implies that the authors were unable to provide original, verifiable raw data to support their published figures or to explain the duplication.

Broader Implications for Research Integrity

This case serves as a significant example of the challenges facing modern scientific publishing:

  • Data Duplication and "Paper Mills": The reuse of images across different journals is a common indicator of "paper mill" activity, where fraudulent data is recycled to generate multiple publications for different clients.
  • The Importance of Post-Publication Review: The role of the scientific community in scrutinizing published work remains a vital safeguard. In this instance, a vigilant reader was instrumental in identifying the discrepancy and correcting the scientific record.
  • Cross-Journal Vigilance: The detection of duplication across different publishers highlights the need for more robust, automated screening tools to identify image manipulation and reuse during the peer-review process.

Conclusion

The formal retraction of this study nullifies its findings regarding the role of CKS1B in retinoblastoma. While CKS1B remains a protein of interest in oncology, the claims regarding its impact on the MEK/ERK pathway in this specific context are now considered invalid. Researchers are advised to treat the original 2019 study as unreliable and to look toward future, rigorously verified research to explore the true biological functions of CKS1B in ocular malignancies. The retraction serves as a reminder of the ongoing need for transparency and integrity in cancer research.

Summary updated

Abstract

Following the publication of the above paper, it has been drawn to the Editors' attention by a concerned reader that certain of the lumen formation assay data shown in Fig. 5A on p. 112 were strikingly similar to data appearing in different form in another article written by different authors at different research institute, which had already been published in the journal <i>Biomedicine & Pharmacotherapy</i> prior to the submission of this paper to <i>International Journal of Molecular Medicine</i>, and which has also subsequently been retracted. In view of the fact that the contentious data had already apparently been published previously, the Editor of <i>International Journal of Molecular Medicine</i> has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [International Journal of Molecular Medicine 44: 103‑114, 2019; DOI: 10.3892/ijmm.2019.4183].
BibTeX
@article{zeng2024retracted,
  author = {Zhou Zeng and Zhaolin Gao and Zhipei Zhang and Haibo Jiang and Yang Chang-quan and Jie Yang and Xiaobo Xia},
  title = {{[Retracted] Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway}},
  journal = {International Journal of Molecular Medicine},
  year = {2024},
  doi = {10.3892/ijmm.2024.5382},
}
Figure